ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2144

The Association Between Age at Diagnosis and Health-Related Quality of Life in ANCA-Associated Vasculitis

Jessica Bloom1, Kaci Pickett-Nairne2, Lori Silveira1, Cristina Burroughs3, Katrina Bargender4, Amy Bolton4, Christine Yeung4, Jennifer Gordon5, Peter Merkel6 and Karen James7, 1University of Colorado, Aurora, CO, 2University of Colorado, Denver, 3University of South Florida, Tampa, FL, 4Vasculitis Patient-Powered Research Network, Philadelphia, PA, 5Vasculitis Foundation, Kansas City, MO, 6University of Pennsylvania, Philadelphia, PA, 7University of Utah, Salt Lake City, UT

Meeting: ACR Convergence 2025

Keywords: ANCA associated vasculitis, Anxiety, Patient reported outcomes, Pediatric rheumatology, quality of life

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (2124–2158) Pediatric Rheumatology – Clinical Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: ANCA-associated vasculitis (AAV) is a chronic autoimmune condition that significantly impacts patients’ quality of life. It is unknown whether this impact varies based on age at diagnosis, from childhood through older adulthood. This study examined the relationship between age at diagnosis of AAV and health-related quality of life (HRQoL).

Methods: The data source was the Vasculitis Patient-Powered Research Network, an online, longitudinal, prospective cohort of adults with AAV (granulomatosis with polyangiitis, microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis) enrolled from 2014-2024. Cohorts were stratified by age (years) at diagnosis: children (< 18), young adults (18–40), middle-aged adults (41–65), and older adults ( > 65). Descriptive statistics were summarized. Differences were tested via Student’s t-tests or Kruskal-Wallis tests for continuous variables and Pearson’s chi squared tests or Fisher’s exact tests for categorical variables. Multivariable linear regressions assessed associations between age at diagnosis and Patient-Reported Outcomes Measurement Information System (PROMIS) results at last follow-up visit. Models were adjusted for gender and age at HRQoL assessment.

Results: Analysis included 2009 patients with AAV. The majority had GPA and there was a female predominance that decreased with age at diagnosis. Those diagnosed at younger ages had longer follow-up at time of last PROMIS measure (Table 1). All cohorts had impaired HRQoL in every domain (Figure 1). When adjusted for gender and age at HRQoL assessment, those diagnosed with AAV in childhood had worse HRQoL related to anxiety than those diagnosed as young, middle-aged, or older adults. Additionally, those diagnosed in childhood had better HRQoL related to fatigue, sleep disturbance, depression, pain interference, satisfaction with participation in social roles, and physical functioning (Table 2).

Conclusion: Patients with AAV have impaired HRQoL, especially related to anxiety. Additionally, age at diagnosis with AAV is associated with differences in HRQoL. Compared to patients diagnosed with AAV at older ages, those diagnosed at younger ages have worse HRQoL related to anxiety and better HRQoL related to fatigue, sleep disturbance, depression, pain interference, satisfaction with participation in social roles, and physical functioning. Understanding the mechanisms by which age at diagnosis impacts HRQoL will be useful for developing targeted clinical interventions in AAV.

Supporting image 1

Supporting image 2

Supporting image 3Figure 1. Patient-Reported Outcomes Measurement Information System T-Scores Based on Age at Diagnosis with ANCA-associated vasculitis. Boxplot of the distribution of Patient-Reported Outcomes Measurement Information System T-Scores stratified by age at diagnosis with ANCA-associated vasculitis. The boxes represent the 25th to 75th percentile T scores, with the middle line within each box representing the median T score. The solid lines extending out signify the range with dots representing possible outliers. The dashed gray line represents the mean score of the referent general pediatric population (50), with one standard deviation above and below represented in gray. Better health-related quality of life is represented by a lower score in the top five measures and a higher score in the bottom two measures. Statistical significance indicates that the median T score for at least one age at diagnosis group is different from another age at diagnosis group within that measure. *statistical significance at p < 0.05; **statistical significance at p < 0.01.


Disclosures: J. Bloom: None; K. Pickett-Nairne: None; L. Silveira: None; C. Burroughs: None; K. Bargender: None; A. Bolton: None; C. Yeung: None; J. Gordon: None; P. Merkel: AbbVie, 2, 5, Alpine, 2, Amgen, 2, 5, ArGenx, 2, AstraZeneca, 2, 5, Boehringer-Ingelheim, 2, 5, Bristol-Myers Squibb (BMS), 2, 5, CSL Behring, 2, Eicos, 5, Electra, 5, GlaxoSmithKlein (GSK), 2, 5, iCell, 2, Interius, 2, Kinevant, 2, Kyverna, 2, 11, Lifordi, 11, Metagenomia, 2, Neutrolis, 2, 5, 11, Novartis, 2, NS Pharma, 2, Otsuka, 2, Q32, 2, 11, Quell, 2, Regeneron, 2, Sanofi, 2, Sparrow, 2, 11, Takeda, 2, 5, UpToDate, 9, Vistera, 2; K. James: Sobi, 1.

To cite this abstract in AMA style:

Bloom J, Pickett-Nairne K, Silveira L, Burroughs C, Bargender K, Bolton A, Yeung C, Gordon J, Merkel P, James K. The Association Between Age at Diagnosis and Health-Related Quality of Life in ANCA-Associated Vasculitis [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/the-association-between-age-at-diagnosis-and-health-related-quality-of-life-in-anca-associated-vasculitis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-association-between-age-at-diagnosis-and-health-related-quality-of-life-in-anca-associated-vasculitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology